3175 results for «439»
3175 results
TAVI and coronary artery disease
08 Feb 2025 – From PCR Tokyo Valves 2025
Delve into the complex interplay between TAVI and coronary artery disease in this comprehensive session. Explore the decision-making process for optimal sequencing of PCI and TAVI, and examine cases of acute myocardial infarction due to coronary embolism and delayed coronary obstruction following TAVI. Gain insights into...
High-risk TAVI
08 Feb 2025 – From PCR Tokyo Valves 2025
Delve into the management of high-risk TAVI cases in this session. Discover innovative approaches, such as Impella-assisted TAVI in severe bicuspid aortic valve disease with severe left ventricular dysfunction, TAVR for pure native aortic regurgitation in surgically unfit patients, and the use of TAVI as a...
TAVI complex cases: intravascular hemolysis, Heyde syndrome & more
08 Feb 2025 – From PCR Tokyo Valves 2025
This session presents a diverse array of complex TAVI cases, from interventions for paravalvular leak-induced intravascular hemolysis to cases of severe aortic tortuosity, calcification hindering valve expansion, and successful TAVI in patients with Heyde syndrome and HIV infection. Gain valuable insights into navigating these challenging scenarios.
The value of WATCHMAN therapy - Who should we treat?
08 Feb 2025 – From PCR Tokyo Valves 2025
Delve into the value of WATCHMAN therapy in this sponsored session by Boston Scientific. Explore the latest evidence and future perspectives of this innovative treatment option. Understand who the ideal patient is for WATCHMAN therapy and how to identify them in daily clinical practice, including TAVI...
Mitral valve-in-valve and valve-in-ring electrosurgery
08 Feb 2025 – From PCR Tokyo Valves 2025
Future devices for structural heart interventions
08 Feb 2025 – From PCR Tokyo Valves 2025
Get a glimpse into the future of structural heart interventions! This PCR Tokyo Valves 2025 session dives into the latest innovations in imaging and explores groundbreaking devices for mitral and tricuspid valve treatments. Watch as experts discuss how these advancements are set to reshape clinical practice.
Nightmare in TAVI
08 Feb 2025 – From PCR Tokyo Valves 2025
Watch this session replay featuring two challenging cases: valve embolisation with a balloon-expandable valve and coronary obstruction with a self-expandable valve. Learn key lessons from the first case, including the importance of secure pacing, avoiding damage to the descending aorta while retrieving the embolised valve, and...
M-TEER for secondary mitral regurgitation
08 Feb 2025 – From PCR Tokyo Valves 2025
Managing secondary mitral regurgitation with M-TEER requires a tailored approach. This PCR Tokyo Valves 2025 session explores key considerations for atrial functional MR and VFMR beyond COAPT criteria, helping you refine patient selection, procedural strategies, and post-treatment management through expert insights and real-world cases.
Mitral complications
08 Feb 2025 – From PCR Tokyo Valves 2025
TAVI
08 Feb 2025 – From PCR Tokyo Valves 2025
Dive into this comprehensive TAVI session to explore various techniques and strategies for optimizing procedural outcomes. Discover how to align commissures in self-expandable valves, manage sudden deterioration in severe aortic stenosis without pre-operative evaluation, and tackle the unique challenges of rescue TAVI for cardiogenic shock. Additionally,...
Valve-in-valve
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore this comprehensive session on valve-in-valve procedures, covering a wide range of complex scenarios. Gain insights into the first TAVR in a surgically implanted aortic Trifecta valve, TAVI-valve-in-valve double chimney stenting, transcatheter aortic valve replacement in a surgical aortic valve for bioprosthetic valve dysfunction, valve-in-valve for...
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
Three-year results of HOST-POLYTECH-ACS RCT comparing durable- vs. degradable-polymer DES
30 Aug 2023
Alex Sticchi provides his take on the 3-year results of HOST-POLYTECH-ACS RCT which were presented by Hyo-Soo Kim during the ESC 2023 congress in Amsterdam.
Author
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
02 Sep 2025
Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...
Author
Evidence base: A description of the key, so far published, studies in the space of drug coated balloons
23 Jan 2025
Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.
Author
Author
